{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T01:10:27Z","timestamp":1777857027983,"version":"3.51.4"},"reference-count":19,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JND"],"published-print":{"date-parts":[[2022,3,1]]},"abstract":"<jats:p>Background: Glucocorticoid steroids are standard of care in Duchenne Muscular Dystrophy (DMD) to slow disease course. Use of glucocorticoids in other muscular dystrophies, including Becker (BMD) and Limb Girdle (LGMD), has been less explored. Recently, preclinical studies conducted in DMD and LGMD mouse models showed once-weekly prednisone was associated with improved muscle performance without activation of muscle atrophy genes. Objective: To determine safety and tolerability of once-weekly prednisone in patients with LGMD and BMD. Methods: We conducted an open label, exploratory single center study of of once-weekly prednisone at 0.75\u20131\u200amg\/Kg in LGMD (n\u200a=\u200a19) and BMD (n\u200a=\u200a1) (mean age 35, range 18\u201360). The LGMD participants represented multiple different LGMD subtypes, and the study included ambulatory and non-ambulatory participants. Participants were assessed at baseline and 24 weeks for vital signs, blood biomarkers, and for patient-reported side effects. As secondary endpoints, functional muscle testing and body composition were measured. Results: Over the 24-week study, there were no significant changes in blood pressure, HgbA1C, or lipid profiles. We observed a reduction in serum creatine kinase over the study interval. Whole body DEXA scanning suggested a possible increase in lean mass and a reduction in adiposity. Functional measures suggested trends in improved muscle performance. Conclusions: In this single center, open label pilot study, once-weekly prednisone was safe and well tolerated. Additional investigation of once-weekly prednisone in a larger cohort and for a longer period of time is warranted.<\/jats:p>","DOI":"10.3233\/jnd-210741","type":"journal-article","created":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T13:54:20Z","timestamp":1643723660000},"page":"275-287","source":"Crossref","is-referenced-by-count":20,"title":["An Open Label Exploratory Clinical Trial Evaluating Safety and Tolerability of Once-Weekly Prednisone in Becker and Limb-Girdle Muscular Dystrophy"],"prefix":"10.1177","volume":"9","author":[{"given":"Aaron S.","family":"Zelikovich","sequence":"first","affiliation":[{"name":"Center for Genetic Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA"},{"name":"Department of Neurology, Northwestern University School of Medicine, Chicago, Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin C.","family":"Joslin","sequence":"additional","affiliation":[{"name":"Department of Neurology, Northwestern University School of Medicine, Chicago, Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Casey","sequence":"additional","affiliation":[{"name":"Department of Neurology, Northwestern University School of Medicine, Chicago, Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth M.","family":"McNally","sequence":"additional","affiliation":[{"name":"Center for Genetic Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Senda","family":"Ajroud-Driss","sequence":"additional","affiliation":[{"name":"Department of Neurology, Northwestern University School of Medicine, Chicago, Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","reference":[{"issue":"5","key":"10.3233\/JND-210741_ref1","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1097\/WCO.0000000000000739","article-title":"Update in Duchenne and Becker muscular dystrophy","volume":"32","author":"Waldrop","year":"2019","journal-title":"Curr Opin Neurol"},{"issue":"10","key":"10.3233\/JND-210741_ref2","doi-asserted-by":"crossref","first-page":"e0240687","DOI":"10.1371\/journal.pone.0240687","article-title":"Medical management of muscle weakness in Duchenne muscular dystrophy","volume":"15","author":"Rivera","year":"2020","journal-title":"PLoS One"},{"issue":"1","key":"10.3233\/JND-210741_ref3","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3233\/JND-200556","article-title":"Mechanisms and Clinical Applications of Glucocorticoid Steroids in Muscular Dystrophy","volume":"8","author":"Quattrocelli","year":"2021","journal-title":"J Neuromuscul Dis"},{"issue":"5","key":"10.3233\/JND-210741_ref4","first-page":"CD003725","article-title":"Corticosteroids for the treatment of Duchenne muscular dystrophy","author":"Matthews","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.3233\/JND-210741_ref5","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/mus.20646","article-title":"Weekly oral prednisolone improves survival and strength in male mdx mice","volume":"35","author":"Keeling","year":"2007","journal-title":"Muscle Nerve"},{"issue":"5","key":"10.3233\/JND-210741_ref6","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1212\/WNL.0b013e318227b164","article-title":"Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy","volume":"77","author":"Escolar","year":"2011","journal-title":"Neurology"},{"issue":"6","key":"10.3233\/JND-210741_ref7","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/mus.26441","article-title":"Twice-weekly glucocorticosteroids in infants and young boys with Duchenne muscular dystrophy","volume":"59","author":"Connolly","year":"2019","journal-title":"Muscle Nerve"},{"issue":"3","key":"10.3233\/JND-210741_ref8","first-page":"172","article-title":"Current and emerging therapies in Becker muscular dystrophy (BMD)","volume":"38","author":"Angelini","year":"2019","journal-title":"Acta Myol"},{"key":"10.3233\/JND-210741_ref9","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1750-1172-8-26","article-title":"Treatment of dysferlinopathy with deflazacort: A double-blind, placebo-controlled clinical trial","volume":"8","author":"Walter","year":"2013","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"10.3233\/JND-210741_ref10","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.ejpn.2007.02.018","article-title":"Inflammation and response to steroid treatment in limb-girdle muscular dystrophy 2I","volume":"11","author":"Darin","year":"2007","journal-title":"Eur J Paediatr Neurol"},{"issue":"2","key":"10.3233\/JND-210741_ref11","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.nmd.2009.11.005","article-title":"Two siblings with limb-girdle muscular dystrophy type 2E responsive to deflazacort","volume":"20","author":"Wong-Kisiel","year":"2010","journal-title":"Neuromuscul Disord"},{"issue":"6","key":"10.3233\/JND-210741_ref12","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1002\/(SICI)1097-4598(199806)21:6<769::AID-MUS9>3.0.CO;2-5","article-title":"Homozygous alpha-sarcoglycan mutation in two siblings: One asymptomatic and one steroid-responsive mild limb-girdle muscular dystrophy patient","volume":"21","author":"Angelini","year":"1998","journal-title":"Muscle Nerve"},{"issue":"10","key":"10.3233\/JND-210741_ref13","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1590\/0004-282X20140126","article-title":"Clinical aspects of patients with sarcoglycanopathies under steroids therapy","volume":"72","author":"Albuquerque","year":"2014","journal-title":"Arq Neuropsiquiatr"},{"issue":"11","key":"10.3233\/JND-210741_ref14","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1016\/j.ajpath.2017.07.017","article-title":"Intermittent Glucocorticoid Dosing Improves Muscle Repair and Function in Mice with Limb-Girdle Muscular Dystrophy","volume":"187","author":"Quattrocelli","year":"2017","journal-title":"Am J Pathol."},{"key":"10.3233\/JND-210741_ref15","doi-asserted-by":"crossref","unstructured":"Quattrocelli M , Zelikovich AS , Jiang Z , Peek CB , Demonbreun AR , Kuntz NL , et al. Pulsed glucocorticoids enhance dystrophic muscle performance through epigenetic-metabolic reprogramming. JCI Insight. 2019;4(24).","DOI":"10.1172\/jci.insight.132402"},{"issue":"1","key":"10.3233\/JND-210741_ref16","first-page":"8","article-title":"Upper vs lower extremity functional loss in neuromuscular disease","volume":"68","author":"Lord","year":"1987","journal-title":"Arch Phys Med Rehabil"},{"issue":"5","key":"10.3233\/JND-210741_ref17","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1212\/WNL.0000000000002337","article-title":"Practice guideline update summary: Corticosteroid treatment of Duchenne muscular dystrophy: Report of the Guideline Development Subcommittee of the American Academy of Neurology","volume":"86","author":"Gloss","year":"2016","journal-title":"Neurology"},{"issue":"23","key":"10.3233\/JND-210741_ref18","doi-asserted-by":"crossref","first-page":"7153","DOI":"10.1073\/pnas.1507719112","article-title":"Large-scale serum protein biomarker discovery in Duchenne muscular dystrophy","volume":"112","author":"Hathout","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.3233\/JND-210741_ref19","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1002\/mus.25089","article-title":"Clinical trial readiness in non-ambulatory boys and men with duchenne muscular dystrophy: MDA-DMD network follow-up","volume":"54","author":"Connolly","year":"2016","journal-title":"Muscle Nerve"}],"container-title":["Journal of Neuromuscular Diseases"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JND-210741","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T23:49:56Z","timestamp":1777506596000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JND-210741"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,1]]},"references-count":19,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.3233\/jnd-210741","relation":{},"ISSN":["2214-3599","2214-3602"],"issn-type":[{"value":"2214-3599","type":"print"},{"value":"2214-3602","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,1]]}}}